These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 10229898)
1. The role of octreoscan in thyroid eye disease. Krassas GE; Kahaly GJ Eur J Endocrinol; 1999 May; 140(5):373-5. PubMed ID: 10229898 [TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease. Krassas GE; Doumas A; Kaltsas T; Halkias A; Pontikides N Thyroid; 1999 Jan; 9(1):47-52. PubMed ID: 10037076 [TBL] [Abstract][Full Text] [Related]
3. Octreoscan in thyroid-associated ophthalmopathy. Krassas GE Thyroid; 2002 Mar; 12(3):229-31. PubMed ID: 11952044 [TBL] [Abstract][Full Text] [Related]
4. Indium-111-pentetreotide scintigraphy in Graves' ophthalmopathy. Kahaly G; Diaz M; Hahn K; Beyer J; Bockisch A J Nucl Med; 1995 Apr; 36(4):550-4. PubMed ID: 7699440 [TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Krassas GE; Dumas A; Pontikides N; Kaltsas T Clin Endocrinol (Oxf); 1995 Jun; 42(6):571-80. PubMed ID: 7634496 [TBL] [Abstract][Full Text] [Related]
6. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy. Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448 [TBL] [Abstract][Full Text] [Related]
7. Indium-111-pentetreotide in Graves' disease. Kahaly G; Görges R; Diaz M; Hommel G; Bockisch A J Nucl Med; 1998 Mar; 39(3):533-6. PubMed ID: 9529305 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin analog 111In-octreotide. Moncayo R; Baldissera I; Decristoforo C; Kendler D; Donnemiller E Thyroid; 1997 Feb; 7(1):21-9. PubMed ID: 9086565 [TBL] [Abstract][Full Text] [Related]
9. Somatostatin-receptor scintigraphy in Graves' disease: reproducibility and variance of orbital activity. Förster GJ; Krummenauer F; Nickel O; Kahaly GJ Cancer Biother Radiopharm; 2000 Oct; 15(5):517-25. PubMed ID: 11155823 [TBL] [Abstract][Full Text] [Related]
10. [111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity? Postema PT; Krenning EP; Wijngaarde R; Kooy PP; Oei HY; van den Bosch WA; Reubi JC; Wiersinga WM; Hooijkaas H; van der Loos T J Clin Endocrinol Metab; 1994 Dec; 79(6):1845-51. PubMed ID: 7989493 [TBL] [Abstract][Full Text] [Related]
11. Lanreotide in the treatment of patients with thyroid eye disease. Krassas GE; Kaltsas T; Dumas A; Pontikides N; Tolis G Eur J Endocrinol; 1997 Apr; 136(4):416-22. PubMed ID: 9150703 [TBL] [Abstract][Full Text] [Related]
12. Recombinant thyrotropin-induced orbital uptake of [111In-diethylenetriamine-pentacetic acid-D-Phe1]octreotide in a patient with inactive Graves' ophthalmopathy. Savastano S; Pivonello R; Acampa W; Salvatore M; Lombardi G; Colao A; Fenzi G J Clin Endocrinol Metab; 2005 Apr; 90(4):2440-4. PubMed ID: 15687327 [TBL] [Abstract][Full Text] [Related]
13. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide. Breeman WA; Hofland LJ; van der Pluijm M; van Koetsveld PM; de Jong M; Setyono-Han B; Bakker WH; Kwekkeboom DJ; Visser TJ; Lamberts SW Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760 [TBL] [Abstract][Full Text] [Related]
14. 111In-octreotide imaging in patients with long-standing Graves' ophthalmopathy. Bohuslavizki KH; Oberwöhrmann S; Brenner W; Eberhardt JU; Mönig H; Clausen M; Sippel C; Wolf H; Epe B; Henze E Nucl Med Commun; 1995 Nov; 16(11):912-6. PubMed ID: 8587756 [TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptor scintigraphy to predict the clinical evolution and therapeutic response of thyroid-associated ophthalmopathy. Nocaudie M; Bailliez A; Itti E; Bauters C; Wemeau JL; Marchandise X Eur J Nucl Med; 1999 May; 26(5):511-7. PubMed ID: 10382096 [TBL] [Abstract][Full Text] [Related]
16. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide. Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448 [TBL] [Abstract][Full Text] [Related]
17. The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment. Shi W; Buchanan KD; Johnston CF; Larkin C; Ong YL; Ferguson R; Laird J Clin Endocrinol (Oxf); 1998 Mar; 48(3):303-9. PubMed ID: 9578820 [TBL] [Abstract][Full Text] [Related]